Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

NCT01221506 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Pazopanib
DEVICE: DCE-MRI and Quantitative Doppler Ultrasound

Sponsor

Abramson Cancer Center at Penn Medicine